
ADMA Biologics appoints Lawrence Guiheen to board of directors
pharmafile | July 25, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | ADMA Biologics, Lawrence Guiheen
Late-stage biotech firm ADMA Biologics has announced it has appointed Lawrence Guiheen to its board of directors.
Guiheen said: “Having previously served as president of BioPharmaceuticals for Baxter BioScience and the chairman of the global board of directors of the Plasma Protein Therapeutics Association, I am very pleased to join ADMA’s board of directors and look forward to sharing my experience and contributing to the company’s future success.”
“We are very pleased to welcome Larry as a member of our board of directors, added Steven Elms, chairman of the board at ADMA. “We look forward to utilising his vast experience and relationships in the plasma and pharmaceutical industries as we continue to advance our product candidate’s development and expand our FDA-approved plasma operations.”
Guiheen is currently the principal of Guiheen and Associates LLC, a consulting group that specialises in biopharmaceuticals commercialisation. Previous to this, he was president of BioPharmaceuticals for Baxter BioScience, where he managed sales and marketing of plasma and recombinant biotherapeutics in North America.






